InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
InspireMD (NASDAQ: NSPR) will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 12:45 PM ET. A live audio webcast and archived recording will be available on the company’s Investors page.
According to InspireMD, the presentation will cover recent corporate developments and provide an investor update.
Positive
- None.
Negative
- None.
News Market Reaction – NSPR
In the Apr 1 session, NSPR declined 3.68%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Earnings results | Positive | +0.0% | Reported strong Q4 and 2025 revenue growth and provided 2026 guidance. |
| Mar 09 | Earnings date set | Neutral | +0.6% | Announced timing and access details for Q4 and full‑year 2025 results. |
| Jan 20 | Inducement grant | Neutral | +1.3% | Disclosed restricted stock inducement grant to a new non‑executive employee. |
| Jan 12 | Clinical publication | Positive | -5.8% | Published C-GUARDIANS pivotal trial in JACC showing low adverse event rates. |
| Nov 24 | Clinical study data | Positive | +1.6% | Highlighted CREST-2 results supporting carotid artery stenting benefits and CGuard data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News flow has mostly aligned with price, though a prior strong clinical publication saw a negative reaction.
Over the last several months, NSPR highlighted multiple milestones, including JACC publication of the C-GUARDIANS pivotal trial on Jan 12, 2026 and positive CREST-2 study read‑through on Nov 24, 2025. Financially, Q4 and full‑year 2025 results on Mar 18, 2026 showed strong revenue growth. Earlier HR and equity‑grant updates rounded out news flow. Today’s conference participation fits this pattern of ongoing investor‑relations and visibility efforts rather than a discrete financial or clinical catalyst.
Key Terms
carotid stent medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 12:45 pm Eastern Time (ET).
A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com